Current FGF21-related drugs and therapies primarily target obesity and dysregulated glucose and lipid metabolism, including conditions such as liver steatosis, T2DM, and viral hepatitis [204, 205]. The gene discussed is FGF21; the disease is type 2 diabetes mellitus.